Citations

Citations to this article as recorded by  

• Sodium‐glucose cotransporter 2 inhibitor ameliorates thiazolidinedione‐induced fluid retention through vascular leakage reduction in white adipose tissue
  Ji Yoon Kim, Hye‐Min Jang, Hye‐Jin Lee, Ah Hyeon Lee, Dong‐Hoon Kim, Sin Gon Kim, Nam Hoon Kim
  Diabetes, Obesity and Metabolism.2026; 28(3): 1764.     CrossRef
• Molecular mechanisms of PCSK9 in cardiology: therapeutic implications and clinical impacts on the cardiorenal axis
  Sandeep Kaur, Drishti Panjwani, Shareen Singh, Souvik Banerjee, Sukriti Wadehra, Amritpal Kaur, Thakur Gurjeet Singh
  Molecular and Cellular Biochemistry.2026;[Epub]     CrossRef
• Hepatorenal vulnerability flagged by glomerular hyperfiltration in metabolic liver disease: a large health-screening cohort evidence
  Dae-Jeong Koo, Yun Tae Kim, Sun-Joon Moon, Hyemi Kwon, Se Eun Park, Sang Min Lee, Cheol-Young Park, Won-Young Lee, Sung Rae Cho, Eun-Jung Rhee
  Diabetology & Metabolic Syndrome.2026;[Epub]     CrossRef
• Effects of SGLT2 inhibitors on NSAID-associated acute kidney injury in type 2 diabetes: a claims-based cohort study
  Yuki Kunitsu, Hiroyoshi Koide, Keiko Ikuta, Daiki Hira, Shunsaku Nakagawa, Masahiro Tsuda, Shin-Ya Morita, Tomohiro Terada
  BMC Nephrology.2026;[Epub]     CrossRef
• Redefining SGLT2 inhibitors through cytoprotective mechanisms
  Sanja Stankovic, Zoran Miloradovic, Vladimir Petrovic, Milan Stoiljkovic
  European Journal of Pharmacology.2026; 1016: 178647.     CrossRef
• Analysis of the Endocrine Responses to Anti-Diabetes Drugs: An Issue of Elevated Plasma Renin Concentration in Sodium-Glucose Co-Transporter 2 Inhibitor
  Cheng-Wei Lin, Shih-Yuan Hung, I-Wen Chen
  International Journal of General Medicine.2025; Volume 18: 135.     CrossRef
• Advances in understanding and managing diabetic kidney disease: An updated review
  Elmukhtar Habas, Amnna Rayani, Aml Habas, Kalifa Farfar, Eshrak Habas, Khaled Alarbi, Ala Habas, Elmehdi Errayes, Gamal Alfitori
  Ukrainian Journal of Nephrology and Dialysis.2025; (1(85)): 66.     CrossRef
• Dietary Polyunsaturated Fatty Acid Deficiency Impairs Renal Lipid Metabolism and Adaptive Response to Proteinuria in Murine Renal Tubules
  Yaping Wang, Pan Diao, Daiki Aomura, Takayuki Nimura, Makoto Harada, Fangping Jia, Takero Nakajima, Naoki Tanaka, Yuji Kamijo
  Nutrients.2025; 17(6): 961.     CrossRef
• Diuretics: a review of the pharmacology and effects on glucose homeostasis
  Mauricio Di Fulvio, Yakshkumar Dilipbhai Rathod, Shorooq Khader
  Frontiers in Pharmacology.2025;[Epub]     CrossRef
• SGLT2 Inhibitors in Cancer Patients: A Comprehensive Review of Clinical, Biochemical, and Therapeutic Implications in Cardio-Oncology
  Alessandra Greco, Maria Laura Canale, Vincenzo Quagliariello, Stefano Oliva, Andrea Tedeschi, Alessandro Inno, Marzia De Biasio, Irma Bisceglia, Luigi Tarantini, Nicola Maurea, Alessandro Navazio, Marco Corda, Attilio Iacovoni, Furio Colivicchi, Massimo G
  International Journal of Molecular Sciences.2025; 26(10): 4780.     CrossRef
• Dual-faced guardians: SGLT2 inhibitors’ kidney protection and health challenges: a position statement by Kasralainy nephrology group (KANG)
  Amin Roshdy Soliman, Mohamed Elkhatib, Sahier El-Khashab, Rasha Ahmed Darwish, Ahmed Fayed, Tarek S. Abdelaziz, Hany Hammad, Rabab Mahmoud Ahmed, Hoda Abdelhamid Maamoun
  Diabetology & Metabolic Syndrome.2025;[Epub]     CrossRef
• Cardiovascular and Renal Outcomes Following Repeated Naringenin Exposure in Normotensive and Hypertensive Rats
  Anelize Dada, Rita de Cássia Vilhena da Silva, Mariana Zanovello, Anelise Felício Macarini, Thaise Boeing, Valdir Cechinel Filho, Priscila de Souza
  Pharmaceuticals.2025; 18(6): 873.     CrossRef
• Investigating the effect of SGLT2 inhibitors on cardiovascular related health status in HFmrEF and HFpEF: systematic review and meta analysis
  Tabitha Kusi-Yeboah, Isaac Gianfrancesco, Muzammil Arif Din Abdul Jabbar, Phoebe Collins, Dalton James Bally, Juliet Thornton, Kieran Williams, Ayoola Ishola, Lucy Hong, Ping Jing Toong, Milindu Wickramarachchi
  Frontiers in Cardiovascular Medicine.2025;[Epub]     CrossRef
• Sodium-glucose co-transporter 2 inhibitor-induced increase in adenosine promotes lipolysis and weight reduction by activating reno-adipose autonomic neurocircuitry
  Aika Hagiwara, Shintaro Yamaguchi, Kazutoshi Miyashita, Kenichiro Kinouchi, Kaori Hayashi, Hiroshi Itoh
  Hypertension Research.2025; 48(10): 2664.     CrossRef
• Chronic kidney disease in the primary care setting: A narrative review
  Faryal Safdar, Ahsan Aslam
  Journal of General and Family Medicine.2025; 26(5): 385.     CrossRef
• Determining the role of SGLT2 inhibitors (dapagliflozin) on progression of proteinuria among non-diabetic adult patients with chronic kidney disease: a randomized controlled trial
  Shivam Srivastava, Saurabh Agarwal, Yuvraj Gulati, Alok Kumar Singh, Prakhar Aggarwal
  International Journal of Advances in Medicine.2025; 12(6): 553.     CrossRef
• 2025 Taiwan consensus recommendations for primary care of chronic kidney disease
  Yi-Chun Tsai, Pei-Yu Wu, Tai-Shuan Lai, Chih-Chien Sung, Yi-Wen Chiu, Shang-Jyh Hwang, Yung-Ho Hsu, Mai-Szu Wu, Chung-Liang Shih
  Journal of the Formosan Medical Association.2025;[Epub]     CrossRef
• Bridging Cardiorenal and Hepatic Disease: The Emerging Role of SGLT2 Inhibitors in Cirrhosis
  Omar Alkasabrah, Sameeha Ibrahim, Abdullah Hafeez, Muhammad Qasim Chaudhry, Faiza Jajja, Maharshi Raval, Hritvik Jain, Darshil Maheta, Siddharth Pravin Agrawal, William H. Frishman, Wilbert S. Aronow
  Cardiology in Review.2025;[Epub]     CrossRef
• Efficacy and safety of metformin versus empagliflozin on chronic kidney disease progression (MET-EMPA-CKD): a randomized controlled trial
  Bassant M. Mahboub, Ayman F. Refaie, Sahar M. El-Haggar, Yasser M. Hafez, Tarek M. Mostafa
  Diabetology & Metabolic Syndrome.2025;[Epub]     CrossRef
• Results from a cross-specialty consensus on optimal management of patients with chronic kidney disease (CKD): from screening to complications
  Mustafa Arici, Samir Helmy Assaad-Khalil, Marcello Casaccia Bertoluci, Jason Choo, Yau-Jiunn Lee, Magdalena Madero, Guillermo Javier Rosa Diez, Vicente Sánchez Polo, Sungjin Chung, Teerawat Thanachayanont, Carol Pollock
  BMJ Open.2024; 14(3): e080891.     CrossRef
• Chronic Kidney Disease and SGLT2 Inhibitors
  Eun Sil Koh, Sungjin Chung
  The Journal of Korean Diabetes.2024; 25(1): 16.     CrossRef
• Genitourinary Tract Infections in Patients Taking SGLT2 Inhibitors
  Veraprapas Kittipibul, Zachary L. Cox, Supavit Chesdachai, Mona Fiuzat, JoAnn Lindenfeld, Robert J. Mentz
  Journal of the American College of Cardiology.2024; 83(16): 1568.     CrossRef
• Effects of Sodium–Glucose Co-Transporter 2 Inhibitors on Serum Chloride Concentrations in Patients with Heart Failure
  Ivana Jurin, Vanja Ivanović Mihajlović, Zrinka Šakić, Marin Pavlov, Tomislav Šipić, Petra Vitlov, Hrvoje Falak, Danijela Grizelj, Šime Manola, Mario Udovičić
  Journal of Cardiovascular Development and Disease.2024; 11(11): 364.     CrossRef
• Hemodynamic Effects of SGLT2 Inhibitors in Patients with and Without Diabetes Mellitus—A Narrative Review
  Roxana Brata, Andrei Vasile Pascalau, Ovidiu Fratila, Ioana Paul, Mihaela Mirela Muresan, Andreea Camarasan, Tiberia Ilias
  Healthcare.2024; 12(23): 2464.     CrossRef
• Synopsis of the Korean Society of Nephrology 2023 Practical Recommendations for the Management of Diabetic Kidney Disease
  Sungjin Chung
  The Korean Journal of Medicine.2023; 98(6): 270.     CrossRef